British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

UnitedHealth CEO Andrew Witty is stepping down for personal reasons and the nation's largest health insurer suspended its ...

UnitedHealth Group said Chief Executive Andrew Witty stepped down for “personal reasons” after presiding over a punishing ...

With a neutral sentiment as of May 8, 2025, according to Moneycontrol analysis, GlaxoSmithKline Pharmaceuticals demonstrates ...

With the stock's current price at Rs 2819.60, GlaxoSmithKline Pharmaceuticals is navigating through market dynamics, ...

GlaxoSmithKline Pharmaceuticals reported a 36% increase in net profit to Rs 263 crore in the March quarter, up from Rs 194 ...

GlaxoSmithKline Pharmaceuticals, operating in the Pharmaceuticals sector and classified as a Midcap on the BSE, currently has its share price at ₹2827.05. The stock has experienced fluctuations ...

May 13 (Reuters) - India's GlaxoSmithKline Pharmaceuticals (GLAX.NS), opens new tab reported a higher fourth-quarter profit on Tuesday, led by steady demand for its generic drugs. The Indian unit ...

Witty will act as a senior advisor to his successor, Stephen Hemsley, who served as UnitedHealth Group’s CEO from 2006 to ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.00. The company’s shares closed today ...

India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its ...